Evidence map›Paper›PMID 17951612›Full record

ArticleProtein engineering, design & selection : PEDS2007

Rational design of a chimeric endonuclease targeted to NotI recognition site.

Penghua Zhang, Yongming Bao, Lauren Higgins, Shuang-yong Xu

Open access · hybridAbstract read
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Evolution of sequence specificity in a restriction endonuclease by a point mutation.Proceedings of the National Academy of Sciences of the United States of America · 2008
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Penghua ZhangNew England Biolabs, Inc., 240 County Road, Ipswich, MA 01938, USA.
Yongming Bao
Lauren Higgins
Shuang-yong Xu
New England Biolabs (United States) · US

Funding

A universal DNA endonucleaseR43GM073345 · NIGMS · NEW ENGLAND BIOLABS, INC. · PI XU, SHUANG-YONG · 2005 to 2005
$100k
NIGMS NIH HHS 1R43 GM073345-01NIGMS NIH HHS R43 GM073345
6 · The paper itself

Abstract

A cleavage-deficient variant of NotI restriction endonuclease (GCGGCCGC) was isolated by random mutagenesis of the notIR gene. The NotI variant D160N was shown to bind DNA and protect plasmid DNA from EagI (CGGCCG) and NotI digestions. The EDTA-resistant BmrI restriction endonuclease cleaves DNA sequence ACTGGG N5/N4. The N-terminal cleavage domain of BmrI (residues 1-198) with non-specific nuclease activity was fused to the NotI variant D160N with a short linker. The engineered chimeric endonuclease (CH-endonuclease) recognizes NotI sites specifically in the presence of high salt (100-150 mM NaCl) and divalent cations Mg++ or Ca++. In contrast to wild-type NotI, which cuts within its recognition sequence, BmrI198-NotI (D160N) cleaves DNA outside of NotI sites, resulting in deletion of the NotI site and the adjacent sequences. The fusion of the BmrI cleavage domain to cleavage-deficient variants of Type II restriction enzymes to generate novel cleavage sites will provide useful tools for DNA manipulation.

Indexed as

Drug DesignBase SequenceDeoxyribonucleases, Type II Site-SpecificDNA CleavageElectrophoresis, Polyacrylamide GelMolecular Sequence DataMutant Chimeric ProteinsProtein Structure, TertiaryRecombinant Fusion ProteinsSequence DeletionSubstrate SpecificityTemperatureDeoxyribonucleases, Type II Site-Specificendodeoxyribonuclease XmaIIIGCGGCCGC-specific type II deoxyribonucleasesMutant Chimeric ProteinsRecombinant Fusion Proteins

Identifiers

PMID17951612
PMCPMC2268093
OpenAlexW2143084779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.